ABA SVP Paul Benda discusses how COVID-19 case count growths are slowing, looks at Israel’s skyrocketing case count and why it may not be a good analog to the U.S., discusses what full FDA approval of the Pfizer vaccine means, examines some of the items OSHA is looking at and considers just how long does that N95 mask you have actually lasts.

Paul Benda welcomes you to ABA’s twentieth episode of the weekly Pandemic Update podcast. Once again, it’s all about the Delta variant, which now likely makes up 99% of US cases. This week, Benda discusses current and potential future trends, hospitalization rates—including children—and shares some exciting news about booster shots. He also parses some data on vaccine effectiveness from Israel and newly released CDC studies, and discusses updated OSHA recommendations.

Paul Benda welcomes you to ABA's twentieth episode of the weekly Pandemic Update podcast. Again, not much good news to report this week. Benda discusses the continued spread of Delta and the potential to ration care in some states. He introduces some data on masks and mask recommendations for kids, a new journal article proving COVID is airborne, and a potential timeline for full FDA approval of the vaccine and what it might mean for off-label use. To round it out, he provides some not so good news on the effectiveness of recovered immunity in comparison to vaccine immunity.

In this episode of the ABA Pandemic Update, Paul Benda breaks down the science behind the Delta variants' hyper-infectious nature. It’s all Delta all the time and things keep getting worse and likely to get worse before it gets better. He reviews vaccine effectiveness with Delta, the breakthrough Provincetown cluster, and how to mitigate your risk of getting infected.

On the latest ABA Pandemic Update, Paul Benda does not have much good news to report. He discusses the Delta surge, vaccine effectiveness and safety, new CDC mask guidance, an unwelcome delay on the COVID vaccine for those 12 and under, and he tries to figure out how bad things will get before they get better.

In this episode of the ABA Pandemic Update, ABA SVP Paul Benda discusses the Delta variant and some ways parents can think about the risk it poses to their kids who can’t be vaccinated, examines a poll about common misconceptions regarding the effectiveness of different mitigating actions like hand-washing, looks at the FDA announcement about their review of the Pfizer vaccine for full licensure and talks travel trends and what it means for the future.

ABA SVP Paul Benda returns with a Pandemic Update after a brief hiatus, and unfortunately things have changed substantially in the last two weeks. Today it’s all about the delta variant. Benda talks about how and why cases are trending upward, shares some good news on recovered immunity, examines what schools may look like in the fall, and touches on the need for booster doses.

ABA SVP Paul Benda discusses getting a booster shot if you’ve had Johnson and Johnson vaccine, delta variant-driven increases in cases in the central part of the country, how delta has affected the U.K. and Israel, a Kaiser Family Foundation survey about businesses and vaccines, the real risk from vaccine-induced myocarditis and a new paper that provides hope that most of the population may not need any booster shots.

ABA SVP Paul Benda covers the Delta variant of COVID-19 and its impact on younger populations, reviews vaccine effectiveness, looks at computer models and where they think we’ll be this fall, reviews a new study on how well vaccines work on those with cancer and examines how birthday parties may have contributed to the spread of COVID.

ABA's Paul Benda discusses about some new vaccine data from Novavax, the effect the Delta variant is having on the UK and how it’s spreading in the U.S., the FDA meeting regarding vaccinations for kids, whether vaccines causing heart inflammation and some updates on the legality of vaccine mandates and OSHA’s emergency temporary standard.